We are L-Arginine CAS:74-79-3 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
A nonessential amino acid in human. It is a substrate of nitric oxide synthase, which is converted to L-citrulline and nitric oxide (NO). It is widely used as an ingredient in infusion and infant formula.
|Specification||White crystals or crystalline powder, characteristic odor, characteristic taste|
|Applications||Infusion, Cell culture media, Biotech, Dietary Supplement|
|STORAGE||Controlled room temperature in tight container|
SPECIFICATION AND PROCEDURE
| State of solution
|Not Less Than 98.0%|
|Ammonium (NH4)||Not More Than 0.020%|
|Chloride (Cl)||Not More Than 0.020%|
|Sulfate (SO4)||Not More Than 0.020%|
|Iron (Fe)||Not More Than 10 ppm|
|Heavy metals (Pb)**||Not More Than 10 ppm|
|Arsenic (As2O3)||Not More Than 1 ppm|
|Loss on drying||Not More Than 0.50%|
|Residue on ignition||Not More Than 0.10%|
|Related substances||Not More Than 0.4%|
|Endotoxin*||Less Than 6.0 EU/g|
|Assay (dry basis)||99.0～101.0%|
· * The endotoxin-certified grade will be supplied on request.
· ** FCC grade (Lead : Not More Than 5 mg/kg) will be supplied on request.
· This product meets requirements of residual solvents listed in the current JP, USP and EP.
Related News: Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.3-Bromo-2-chloro-5-methylpyridine Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.Tricloro (3,3,3-trifluoropropil) silano CAS:592-09-6 As far as chemical raw materials are concerned, China occupies a large share in the field of bulk raw materials and has become one of the world’s largest suppliers of chemical raw materials.151103-09-2 This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.The move could force international drugmakers to further cut prices and enable copycat medicines to replace imported off-patent brands at faster pace.